What is VK2735?
A GIP/GLP-1 dual agonist from Viking Therapeutics, tested as a weekly injection and an oral tablet.
VK2735 in the library · Metabolic & Weight Peptides · Human Trials · What are peptides?
8 registered trials · 1 indexed papers
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
What it is
VK2735 is described as a dual GIP and GLP-1 receptor agonist, in the same class as tirzepatide.
Mechanism (as described)
- It activates both incretin receptors.
Status
Investigational (phase 3).
Registered human trials (8)
| Trial | Phase | Status | Year | Enrolled |
|---|---|---|---|---|
| Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) | Phase 3 | not yet recruiting | 2026 | 560 |
| Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) | Phase 3 | not yet recruiting | 2026 | 560 |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | Phase 3 | active not recruiting | 2025 | 1100 |
| VK2735 for Weight Management Phase 3 | Phase 3 | active not recruiting | 2025 | 4500 |
| A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities | Phase 1 | recruiting | 2025 | 270 |
| VK2735 for Weight Management Phase 2 (Venture Oral Dosing) | Phase 2 | completed | 2024 | 280 |
| VK2735 for Weight Management Phase 2 | Phase 2 | completed | 2023 | 176 |
| Phase 1 Study to Evaluate the Safety and Tolerability of VK2735 | Phase 1 | completed | 2021 | 92 |
Peer-reviewed studies (1)
| Paper | Authors | Journal | Year | Type |
|---|---|---|---|---|
| Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study | Bays HE et al. | Obesity (Silver Spring, Md.) | 2026 | Randomized Controlled Trial |
Conditions researched
Related compounds
- CagriSema (Cagrilintide + Semaglutide)
- Cotadutide
- Dulaglutide
- Exenatide
- Liraglutide
- Pemvidutide
- ACTH (Corticotropin)
- ANP (Atrial Natriuretic Peptide)
- Alpha-MSH
- Amycretin
FAQ
How many registered human trials study VK2735?
The PeptideWhiz trial index lists 8 registered trials for VK2735, the most recent from 2026.
How much published research exists on VK2735?
The PeptideWhiz paper index links 1 PubMed paper to VK2735.
Which conditions is VK2735 researched for?
Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes.
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).